RT Journal Article
SR Electronic
T1 SARS-CoV-2 vaccine antibody response and breakthrough infection in dialysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.12.21264860
DO 10.1101/2021.10.12.21264860
A1 Anand, Shuchi
A1 Montez-Rath, Maria E.
A1 Han, Jialin
A1 Garcia, Pablo
A1 Cadden, LinaCel
A1 Hunsader, Patti
A1 Morgan, Curt
A1 Kerschmann, Russell
A1 Beyer, Paul
A1 Dittrich, Mary
A1 Block, Geoffrey A
A1 Chertow, Glenn M
A1 Parsonnet, Julie
YR 2021
UL http://medrxiv.org/content/early/2021/10/14/2021.10.12.21264860.abstract
AB Background Patients receiving dialysis are a sentinel population for groups at high risk for death and disability from COVID-19. Understanding correlates of protection post-vaccination can inform immunization and mitigation strategies.Methods Monthly since January 2021, we tested plasma from 4791 patients receiving dialysis for antibodies to the receptor-binding domain (RBD) of SARS-CoV-2 using a high-throughput assay. We qualitatively assessed the proportion without a detectable RBD response and among those with a response, semiquantitative median IgG index values. Using a nested case-control design, we matched each breakthrough case to five controls by age, sex, and vaccination-month to determine whether peak and pre-breakthrough RBD IgG index values were associated with risk for infection post-vaccination.Results Among 2563 vaccinated patients, the proportion without a detectable RBD response increased from 6.6% [95% CI 5.5-8.1] in 14-30 days post-vaccination to 20.2% [95% CI 17.1-23.8], and median index values declined from 92.7 (95% CI 77.8-107.5) to 3.7 (95% CI 3.1-4.3) after 5 months. Persons with SARS-CoV-2 infection prior-to-vaccination had higher peak index values than persons without prior infection, but values equalized by 5 months (p=0.230). Breakthrough infections occurred in 56 patients, with samples collected a median of 21 days pre-breakthrough. Peak and pre-breakthrough RBD values <23 (equivalent to <506 WHO BAU/mL) were associated with higher odds for breakthrough infection (OR: 3.7 [95% CI 2.0-6.8] and 9.8 [95% CI 2.9-32.8], respectively).Conclusions The antibody response to SARS-CoV-2 vaccination wanes rapidly, and in persons receiving dialysis, the persisting antibody response is associated with risk for breakthrough infection.Competing Interest Statement LC, PH, CM, RK and PB are employed by Ascend Clinical Laboratories. MD and GB are employed by US Renal Care. GC is on the Board of Satellite Healthcare, a not for profit dialysis organization. Funding StatementAscend Clinical Laboratory supported the remainder plasma testing for SARS-CoV2 antibodies. Dr. Anand was supported by R01DK127138. Dr. Garcia is supported by the Leeds Scholarship Fund. Dr Chertow was supported by K24DK085446. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received ethics approval from Stanford University. Stanford University investigators received anonymized data, and the Institutional Review Board waived requirement for consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData may be available upon review and approval of analysis request by all co-authors. Data may require data sharing agreements.